LIDDS initiates research collaboration with the Karolinska Institute

LIDDS initiates research collaboration with the Karolinska Institute
9 november, 2017 admin.adstream

LIDDS has entered a research collaboration with the Department of Laboratory Medicine at Karolinska Institute, Sweden. The collaboration regards fundamental preclinical studies on formulations based on the NanoZolid® technology, as well as access to risk laboratories for formulation development.

LIDDS broadens its R&D activities to develop novel NanoZolid® formulations for local tumor therapy by establishing a collaboration with Professor Mustapha Hassan and Dr. Ying Zhao at the Department of Laboratory Medicine (LABMED) at Karolinska Institute in Huddinge.

–    LIDDS appreciate very much the collaboration with KI, and I am confident that the ongoing collaborative research will be fruitful and supportive to develop new efficient formulations with the NanoZolid® technology. We are also pleased with the preclinical expertise that we have encountered at the Department Laboratory Medicine at Novum, states CEO of LIDDS Monica Wallter.

The collaboration includes fundamental preclinical studies and gives access to risk laboratories for formulation development with hazardous substances. Within the frame of the collaboration, novel NanoZolid® formulations will be investigated prior to entering the clinical phase.

For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com                     

LIDDS is required to disclose the information in this press release under the European Union’s Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 9 November 2017 at 08.00 CET.
                 
About Lidds
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid® technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid® can be combined with both large and small pharmaceutical molecules, such as antibodies. The company’s most advance project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid®is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq, First North. Redeye AB is a certified adviser to LIDDS AB. For more information, go to www.liddspharma.com.